Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future

被引:17
作者
Baldanti, Fausto [1 ]
Ganguly, Nirmal K. [2 ]
Wang, Guiqiang [3 ]
Moeckel, Martin [4 ]
O'Neill, Luke A. [5 ]
Renz, Harald [6 ,7 ]
dos Santos Ferreira, Carlos Eduardo [8 ]
Tateda, Kazuhiro [9 ]
Van der Pol, Barbara [10 ]
机构
[1] Univ Pavia, Diagnost & Pediat Sci, Pavia, Italy
[2] Indian Council Med Res, New Delhi, India
[3] Peking Univ First Hosp, Ctr Liver Dis, Beijing, Peoples R China
[4] Charite, Berlin, Germany
[5] Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin, Ireland
[6] Philipps Univ Marburg, Univ Hosp Giessen & Marburg GmbH, Mol Diagnost, Inst Lab Med & Pathobiochem, Giessen, Germany
[7] IM Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergol, Moscow, Russia
[8] Albert Einstein Hosp, Sao Paulo, Brazil
[9] Toho Univ, Sch Med, Dept Microbiol & Infect Dis, Tokyo, Japan
[10] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA
关键词
SARS-CoV-2; molecular testing; PCR; point-of-care testing; antigen testing; CYCLE THRESHOLD VALUES; CLINICAL-PERFORMANCE; INFLUENZA ACTIVITY; ANTIGEN TESTS; COVID-19; ANTIBODY; METAANALYSIS; MANAGEMENT; ACCURACY; RNA;
D O I
10.1080/10408363.2022.2045250
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A plethora of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic tests are available, each with different performance specifications, detection methods, and targets. This narrative review aims to summarize the diagnostic technologies available and how they are best selected to tackle SARS-CoV-2 infection as the pandemic evolves. Seven key settings have been identified where diagnostic tests are being deployed: symptomatic individuals presenting for diagnostic testing and/or treatment of COVID-19 symptoms; asymptomatic individuals accessing healthcare for planned non-COVID-19-related reasons; patients needing to access emergency care (symptom status unknown); patients being discharged from healthcare following hospitalization for COVID-19; healthy individuals in both single event settings (e.g. airports, restaurants, hotels, concerts, and sporting events) and repeat access settings (e.g. workplaces, schools, and universities); and vaccinated individuals. While molecular diagnostics remain central to SARS-CoV-2 testing strategies, we have offered some discussion on the considerations for when other tools and technologies may be useful, when centralized/point-of-care testing is appropriate, and how the various additional diagnostics can be deployed in differently resourced settings. As the pandemic evolves, molecular testing remains important for definitive diagnosis, but increasingly widespread point-of-care testing is essential to the re-opening of society.
引用
收藏
页码:445 / 459
页数:15
相关论文
共 50 条
  • [21] Evaluation of the Diagnostic Performance of a SARS-CoV-2 and Influenza A/B Combo Rapid Antigen Test in Respiratory Samples
    Dinc, Harika Oykue
    Karabulut, Nuran
    Alacam, Sema
    Uysal, Hayriye Kirkoyun
    Dasdemir, Ferhat Osman
    Onel, Mustafa
    Tuyji Tok, Yesim
    Sirekbasan, Serhat
    Agacfidan, Ali
    Gareayaghi, Nesrin
    cakan, Huseyin
    Eryigit, Onder Yuksel
    Kocazeybek, Bekir
    DIAGNOSTICS, 2023, 13 (05)
  • [22] Diagnostic performances and thresholds: The key to harmonization in serological SARS-CoV-2 assays?
    Plebani, Mario
    Padoan, Andrea
    Negrini, Davide
    Carpinteri, Benedetta
    Sciacovelli, Laura
    CLINICA CHIMICA ACTA, 2020, 509 : 1 - 7
  • [23] Evaluation of a SARS-CoV-2 antigen-detecting rapid diagnostic test as a self-test: Diagnostic performance and usability
    Cassuto, Nino Guy
    Gravier, Anne
    Colin, Mathilda
    Theillay, Aurelie
    Pires-Roteira, Daniela
    Pallay, Sandra
    Serreau, Raphael
    Hocqueloux, Laurent
    Prazuck, Thierry
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (12) : 6686 - 6692
  • [24] Is It Possible to Test for Viral Infectiousness? The Use Case of (SARS-CoV-2)
    Mostafa, Heba H.
    CLINICS IN LABORATORY MEDICINE, 2024, 44 (01) : 85 - 93
  • [25] Considerations for the selection of tests for SARS-CoV-2 molecular diagnostics
    Erbak Yilmaz, Huriye
    Iscan, Evin
    Oz, Ozden
    Batur, Tugce
    Erdogan, Aybike
    Kilic, Seval
    Mutlu, Zeynep
    Yilmaz, Murat
    Spring, Kevin J.
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (10) : 9725 - 9735
  • [26] Technical considerations to development of serological tests for SARS-CoV-2
    Ernst, Emilie
    Wolfe, Patricia
    Stahura, Corrine
    Edwards, Katie A.
    TALANTA, 2021, 224
  • [27] SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges
    Shah, Kevin S.
    Hale Hammond, Mary Elizabeth
    Drakos, Stavros G.
    Anderson, Jeffrey L.
    Fang, James C.
    Knowlton, Kirk U.
    Shaw, Robin M.
    FUTURE CARDIOLOGY, 2021, 17 (07) : 1277 - 1291
  • [28] SARS-CoV-2 neutralising antibody therapies: Recent advances and future challenges
    Liu, Mingtao
    Liang, Zhiman
    Cheng, Zhangkai J.
    Liu, Li
    Liu, Qiwen
    Mai, Yiyin
    Chen, Huihuang
    Lei, Baoying
    Yu, Shangwei
    Chen, Huihui
    Zheng, Peiyan
    Sun, Baoqing
    REVIEWS IN MEDICAL VIROLOGY, 2023, 33 (05)
  • [29] Glycosylation is a key in SARS-CoV-2 infection
    Reis, Celso A.
    Tauber, Rudolf
    Blanchard, Veronique
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2021, 99 (08): : 1023 - 1031
  • [30] The challenges of containing SARS-CoV-2 via test-trace-and-isolate
    Contreras, Sebastian
    Dehning, Jonas
    Loidolt, Matthias
    Zierenberg, Johannes
    Spitzner, F. Paul
    Urrea-Quintero, Jorge H.
    Mohr, Sebastian B.
    Wilczek, Michael
    Wibral, Michael
    Priesemann, Viola
    NATURE COMMUNICATIONS, 2021, 12 (01)